Table 3.
Glycated hemoglobin (HbA1c), body mass index (BMI), and serum lipids at baseline (on IR-HC treatment) and at 6 months after switching to DR-HC treatment in Group A and Group B.
| GROUP A | ||||||
|---|---|---|---|---|---|---|
| IR-HC (tid: 15 + 10 + 5 mg) | DR-HC (bid: 20 + 5 mg) | P-value | ||||
| BMI | 24.5 (24.0–30.0) | 23.5 (20.0–28.0) | 0.004 | |||
| HbA1c | 41 (40–42) | 37 (35–40) | 0.005 | |||
| Total Cholesterol | 238 (222–245) | 209 (192–220) | 0.005 | |||
| HDL | 75 (68–84) | 72.5 (67.0–78.0) | 0.79 | |||
| Triglycerides | 134 (110–162) | 100 (83–143) | 0.007 | |||
| LDL | 133.7 (125.6–140.6) | 115.4 (89.2–125) | 0.03 | |||
| GROUP B | ||||||
| IR-HC (bid: 15 + 10 mg) | DR-HC (20 mg die) | P-value | ||||
| BMI | 29 (24–33) | 27 (24–32) | 0.007 | |||
| HbA1c | 34 (33–38) | 32 (31–35) | 0.004 | |||
| Total Cholesterol | 223 (205–243) | 183 (171–207) | 0.005 | |||
| HDL | 50 (41–55) | 60 (54–82) | 0.07 | |||
| Triglycerides | 113 (102–145) | 100 (87–110) | 0.007 | |||
| LDL | 144 (121–177) | 90 (82–113) | 0.005 | |||
Data analyzed using the Wilcoxon Rank-Sum Test. Bid, divided in two doses; DR-HC, dual release HC; HDL, high-density lipoprotein; IR-HC, immediate-release hydrocortisone; LDL, low-density lipoprotein; tid, divided in three doses.